Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Disputes with Former Executives
?Action No. CV2017-052804
On March 9, 2017, Mr. Dave Engert filed a lawsuit in Arizona and then later changed the venue to Federal Court in Southern California claiming, among other issues, that monies are owed to him under his Consulting Agreement and that his termination was without cause. On October 23, 2017, the Company filed a response and counterclaims against Mr. Engert for an amount exceeding $100,000. The counterclaims include possible fraud and negligence committed by Mr. Engert and Mr. J. Michael Redmond, former successor Chairman of Mr. Engert, director, President and Chief Executive Officer of the Company and former President, Chief Executive Officer, Chairman and director of RoxSan Pharmacy, Inc.
On October 8, 2018, a settlement was reached between Mr. Engert and the Company (the “Engert Settlement”). The Engert Settlement includes, among other things, a cash payment to Mr. Engert in the amount of $139,000, and the cancellation of all of Mr. Engert’s equity holdings in the Company. The Engert Settlement resulted in a net loss to the Company of $33,272. On April 10, 2019, a stipulation for dismissal was filed, and the matter has been fully resolved.
?Action No. BC700070
On March 28, 2018, Mr. J. Michael Redmond filed a lawsuit against the Company and RoxSan Pharmacy, Inc. in the United States District Court, Central District of California for an amount exceeding $75,000. The Company intends to vigorously defend against this action. There are counterclaims that include possible fraud and negligence committed by Mr. Redmond, former President, Chief Executive Officer, Chairman and director of the Company and of RoxSan Pharmacy, Inc. An Arbitration is still pending.
RoxSan Dissolution
On May 14, 2018, pursuant to unanimous resolutions of the boards of directors of RoxSan Pharmacy, Inc. and Parallax Health Sciences, Inc., RoxSan filed a Chapter 7 petition in the United States Bankruptcy Court for the Central District of California (the “Court”). Mr. Timothy Yoo was appointed trustee (“Trustee”) on May 15, 2018. In connection with this filing, RoxSan seeks to discharge approximately $5 million of liabilities owed to various parties, and intercompany loans in excess of $1 million owed to Parallax. The Chapter 7 bankruptcy proceeding by RoxSan Pharmacy, Inc. was fully discharged and the case was closed on March 13, 2019, in U.S. Bankruptcy Court, Central District of California.
Due to, among other things, the reduction in RoxSan’s cash flows during 2016 and 2017, RoxSan became delinquent in its payroll tax depository obligations, resulting in a liability owed to federal and state taxing agencies in the aggregate of $1,148,811, which includes $601,148 in taxes withheld from employees (“Trust Fund Taxes”), employer taxes of $183,172, and penalties and interest of $364,491 through December 31, 2018. The liability was included as part of the Chapter 7 bankruptcy petition, and certain portions of the liability may be discharged. However, in accordance with California bankruptcy laws, federal and state Trust Fund Taxes are not dischargeable. The Company has retained a tax resolution specialist and is in communications with the taxing agencies in order to resolve RoxSan’s liability. During the year ended December 31, 2019, payments for Trust Fund Taxes in the amount of $485,498 were made, and $115,650 in Trust Fund Taxes were outstanding at December 31, 2019.
Settlement Reached:
In January 2019, Melamed requested mediation, seeking settlement of the pending litigation with the Company, including that which was initiated against the Company by her son, Hootan Melamed (Shahla and Hootan, collectively, the “Melameds”). Through mediation, the Company and the Melameds reached agreeable settlement terms, and on February 19, 2020, the Company received a counter-signed Settlement and Release Agreement (the “Settlement”). Effective February 12, 2020 (the “Effective Date”), the Settlement is by and between Parallax Health Sciences, Inc., RoxSan Pharmacy, Inc., Michael Redmond, Edward Withrow III, Huntington Chase Financial Group, LLC, Calli Bucci and Dave Engert (collectively, “Parallax”), and Shahla Melamed and Hootan Melamed (collectively, the “Melameds”), and resolves all pending lawsuits between the parties in connection with the acquisition of RoxSan Pharmacy.
In consideration of the resolution of all existing and potential claims, including the cancellation of the Company’s contingent liability in the principal sum of $20,500,000, and accrued interest of approximately $4,500,000, and without further action or litigation and without admission of liability by either party, the Settlement terms include the following:
?A payment of $4,000,000 (the “Settlement Sum”) to the Melameds, to be paid as follows:
?$1,250,000 within 90 days of the Effective Date;
?$1,250,000 within one (1) year of the Effective Date;
?$1,500,000 within two (2) years of the Effective Date.
?The issuance of ten (10) million shares of the Company’s Common Stock to an entity owned by Shahla Melamed.
In addition, in the event forty percent (40%) or more of the Company and/or its subsidiaries (including by way of merger) is sold within two (2) years of the Effective Date, the Company shall pay the Melameds, within two (2) weeks of receipt of the proceeds from such sale (the “Sale Proceeds”), any outstanding unpaid Settlement Sum plus an additional 10% of the Sale Proceeds received, up to a total of an additional $3,000,000 over and above the Settlement Sum.
In the event the Company fails to cure a breach of timely payment of any portion of the Settlement Sum within thirty (30) days of a notice of default, a Stipulated Judgement may be filed by Melamed in the sum of $20,000,000, less any Settlement Sum amounts previously paid by the Company.
This recently updated website better illustrates the business progress.
https://www.parallaxdiagnostics.com/
Yep, I'd say a pending lawsuit even trumps the old formidable "Skull & Crossbones" ...ask any Yale alumnus!
likely pxyn being sued by the sec had something to do with it too. nobody wants to buy this now no matter the price. current shareholders are now stuck with untradable shares.
This WARNING no doubt had something to do with the lack of volumne...
Warning!!! This security is traded on the Expert Market
The Expert Market is a private market to serve broker-dealer pricing and best execution needs in securities that are restricted from public quoting or trading. Restrictions can be based on issuer requirements, security attributes, investor accreditation and/or suitability risks.
OTC Markets Group Inc. ("OTC Markets") has discontinued the display of quotes on www.otcmarkets.com for this security because it has been labeled Caveat Emptor (Buyer Beware). OTC Markets Group designates certain securities as “Caveat Emptor” and places a skull and crossbones icon next to the stock symbol to inform investors that there may be reason to exercise additional caution and perform thorough due diligence before making an investment decision in that security.
https://www.otcmarkets.com/stock/PRLX/overview
Anyone having luck selling?? I’m not.
It appears this has been turned back on. 2,000 volume this morning and of course it caused me to tank!
there will be no bid.
Never. Try and sell some at the bid and you might get something
Many small caps who offer coronavirus and PPE products were lumped in the same investigation based only on the mention of Covid 19 product lines in the press. I'm confident this company and the press is the real deal. How many scam companies are consistently filing Intellectual Property to protect their inventions and business?
I guess only time will tell, but I'm still confident this will work out in our favor. Spend some time looking into the founder and inventor of some of their Intellectual Property Dr. James Parker, it's a very inspiring story.
Best of luck to all!
It comes down to if the recent statements in the press are factual or not.
lol. the sec determined they were not and suspended.
I'm confident the recent press is legit. It comes down to if the recent statements in the press are factual or not.
PRLX SEC Suspension "because of questions that have been raised about the accuracy and adequacy of information in the marketplace relating to Parallax common stock, including questions relating to statements Parallax made on its website and in press releases on March 12, March 16, March 17, March 23 and March 24, 2020 about its purported development of a rapid screening test for COVID-19 and its purported access to large quantities of COVID-19 diagnostic testing kits and personal protective equipment."
BUT - how long will it take stock buyer confidence to come back? Quite a while I’m sure.
THE SEC JUST SUSPENDED MY STOCK! NOW WHAT?
It happens to almost all penny players. One morning you wake up, grab some coffee, and start checking your stocks, especially that very volatile issue that's been running big. Pre-market Level II is looking good. If all goes well, perhaps today will be the day to take some profit. And then at 9:30, you see something like this:
lEVEL II goes blank. Your heart sinks. If you've had this experience before, you know to go to the SEC website, where your fears are confirmed. Trading has been suspended.
If you're new to the penny arena, you may not have any idea what's going on, so instead you'll go to a message board and try to figure things out. There, you'll probably read conflicting opinions; some will even be reassuring. Pay no attention. Trading suspensions are very bad things. You need to understand what has occurred, and what will occur.
SEC trading suspensions
Suspensions are not to be confused with exchange halts. They are different actions, with different causes and outcomes. Suspensions are the end of the road for most targeted stocks; exchange halts can be survived, and in some cases are positive. The SEC offers an explanation here and here.
The SEC suspends trading in a stock for two basic reasons: the company is a delinquent filer, or fraud is suspected.
Delinquent filers are SEC-registered companies that have failed to submit required annual and quarterly financial reports. Usually the agency sends delinquency notices before taking action; if they are ignored, trading in the company's stock may be suspended without notice. At the same time, the SEC will initiate an administrative proceeding to revoke registration. The company will be served with a letter informing it that it has ten days in which to make some kind of case for its failure to file. If it does not do so, registration will be revoked by default.
What the company does only matters if it hopes to resume trading one day. Several recent cases suggest the SEC is now recommending that issuers who want to make things right should accept revocation, and then get two years of audited filings in order and file a new Form 10. That has the advantage of relieving the company from the obligation to catch up with dozens of old financial reports, which might prove an impossible task, but it has the disadvantage of leaving shareholders in the lurch for as long as it takes to get the filings in, find a sponsoring market maker, and get a Form 211 approved by FINRA. The company may have problems raising money in the interim as well. One issuer that chose this path was Superior Oil & Gas (SIOR), which was suspended on 25 January 2013. Though it initially announced the process could be completed quickly, to date it has filed no Form 10, and has ceased public communication with its investors.
Once registration has been revoked, the stock's ticker will be deleted. Shareholders will still be shareholders, but in a private company. Their stock will be extremely illiquid, and its value will be difficult to determine, as there is no public market for it.
The vast majority of suspended stocks are those of delinquent filers.
Suspensions ordered for suspected violations of the securities laws are more interesting that those ordered for delinquency. Many delinquent filers are entirely dead companies, often without any corporate existence. Companies suspended for suspected fraud have usually been quite active in the recent past, and perhaps are currently active. The three most recent suspensions for cause brought by the agency were of Polar Petroleum Corp (POLR), Biozoom, Inc. (BIZM), and Norstra Energy (NORX), all of which had been trading vigorously just before the SEC brought down the hammer.
7304614700_104fa308f5_zAn explanation of the action is offered in the form of a suspension notice that appears at the SEC website on a dedicated page. The explanations are unfortunately rather vague. They're usually phrased in the form of “questions about” things like possibly misleading press releases or other public statements, the company's operations, and business arrangements like mergers, acquisitions, or buyouts. Sketchy as the information provided is, it at least suggests to observers what the agency is looking at. With the BIZM suspension, the reasons were made a bit clearer: the SEC decided on the action “because of concern that certain Biozoom affiliates and shareholders may have unjustifiably relied upon Rule 144 of the Securities Act of 1933 ('Securities Act') and they, Biozoom, and others may be engaged in an unlawful distribution of securities through the OTCBB.”
That is very clear, and makes perfect sense, given that BIZM is still considered to be a shell company under SEC regulations. BIZM made a fatal error, and will not recover.
The suspension notice also informs market makers that the company has lost compliance with Rule 15c2-11, and so they may no longer make a market in the security, or publish quotations; in addition, it sets a time for the expiration of the suspension. The latter is invariably 11:59 p.m. on the tenth trading day following the announcement of the action. Once upon a time, the SEC was allowed to impose successive suspensions, but an issuer sued, and a Federal judge ruled against the agency. Now it can only suspend for a second time if it can find a different reason to do so.
a
skull-crossbones-pirate-fla
What happens next
During the suspension, the stock will be delisted to the Grey Market as a result of its non-compliance with SEC Rule 15c2-11. Usually that happens a day or two after the action is taken; shareholders can see the change at OTCMarkets. As noted above, that means the MMs won't be able to publish quotations or make a market. They can facilitate trades for brokers, but they are not obliged to fill any orders they may receive. Trades will be matched, though several smaller orders may be set off against a single larger one.
Often hopeful shareholders caught in a suspension tell each other that trading may resume before the ten days have ended. That never happens. Sometimes they convince themselves that it was just a “mistake” on the part of the SEC. It was not. The agency is aware that suspensions are a death sentence, and does not invoke them lightly. Angry investors may rail against Shorty and “bashers,” but the truth is that although the SEC may have originally received tips about problems with the company, they always conduct their own investigation before taking any action.
Some companies issue a press release immediately, usually saying they're “cooperating fully” with the SEC, and are hoping to resolve the problem quickly. Others say nothing at all, or make an announcement when trading resumes. Either way, there is no quick resolution; most of the time there's resolution at all. The SEC will not comment, but warns shareholders that an investigation may be ongoing.
18919886-stressed-businessman-on-his-kneesIn order to resume trading normally, on the Pinks or OTCMarkets' OTCQB tier, the company must find a market maker willing to file a Form 211 to enable it to regain compliance with Rule 15c2-11. The form looks simple enough, but it is not. And there's a special section asking whether the issue has been subject to a trading suspension. When an MM files a 211, it assumes liability. For that reason, they are not generally willing to sponsor a company that's been suspended unless they have very good reason to believe the SEC will not be bringing a further enforcement action. Usually the agency is unwilling to offer such guarantees, and so the stock is left in limbo.
There is a case in which a formerly suspended stock did manage to claw its way back to the Pinks. The issuer was Emergent Health Corporation (EMGE), which explained in a Management's Discussion and Analysis what had happened.. It was suspended in September 2009 because of a pump-and-dump campaign. Management assured the SEC that it'd played no role in the promotion. Evidently they were believed. The SEC sued the perps, and in July 2010 sent a letter to EMGE's attorneys indicating they would not be recommending any further action against the company. In August 2010, a broker-dealer filed a Form 211. Several rounds of comments from FINRA ensued. The company finally returned to the Pinks in early 2011.
Unfortunately, its efforts were too little, too late. It currently trades at around $0.06, and is completely dark.
Bankrupt
When trading resumes
Once the suspension expires, the formerly-suspended stock will reopen on the Grey Market. In most cases, it will trade on the first day, though issues that were illiquid before the action may not. In our initial scenario, I described a hot penny that had attracted a good deal of attention that resulted in heavy buying, the kind that would see interest right away.
Its first day on the Greys will not be heartening for anyone holding. Normally the first trade will be executed shortly after the bell, and will be a lowball. Very low. It may take the stock down as much as 80%. Very likely that the person who ventures that initial trade has entered a market order. Don't be that guy. Wait to see what happens in the next couple of hours. Usually the price will tick up a little. But you still have a problem: you're trading blind. There's no Level II, and no bid or ask. You need to decide what offer you think will be accepted. You'll be able to see executed trades as they happen, and they will give you an idea of what range you should try for. Trading is likely to be extremely volatile, but by the end of the session price will be sharply down; a loss of between 60% to 80% is common.
When a very active stock is suspended, MMs are trapped along with traders. If they've been selling naked to provide liquidity, they may be left with open short positions. They'll want to cover as soon as trading resumes, and therefore will be buyers. Do not, however, imagine that those short positions will be gigantic; they'll only provide a brief window in which volume will be high. So time your exit accordingly. Once they've taken care of themselves they tend to lose interest.
The stock may rise a little in the week or so following its debut on the Greys, but if as it does so, volume will decline, making fills more difficult. It's best not to wait too long, and lose your chance at recovering some of your investment. After weeks, or perhaps a few months, price will plateau for awhile, as volume continues to drop. In the end, liquidity will dry up entirely, and the issue will trade only now and then. Price will drift down slowly.
Here's a chart for Southridge Enterprises (SRGE), a particularly stinky Pink scam that was suspended on 28 December 2012, showing what happened in the succeeding two months. Things have only got worse since then.
Screen Shot 2013-07-01 at 2.20.44 AM
As time goes by, it's possible that the SEC will finally bring closure, in the form of litigation for fraud. In especially outrageous cases, the Department of Justice may join in with a criminal prosecution. It can take as long as two years or more for that to happen. Do not believe anyone who claims that if there's no further action six months after the suspension, somehow all is well.
shredding-cash-223x300In most cases, suspensions for cause don't result in SEC civil lawsuits, much less DOJ prosecutions. The SEC appears to believe that much of the time suspension alone is enough punishment. Often the people behind the suspected fraud are offshore and out of reach. If the SEC can't collect, it makes no sense for them to carry on. They will by then have achieved their object, which is to stop the fraud that provoked the suspension in the first place. If the company is an SEC filer, it will probably stop filing after the suspension; reporting to Edgar is costly, and is pointless for an issuer stuck on the Greys. After a couple of years of delinquency, the SEC may decide to put an end to the story altogether, and will move to revoke registration. That move will not be challenged.
If you're heavily invested, an SEC suspension is an unforgettable nightmare. If a stock you're playing is heavily promoted, or if those Nasty Bashers have raised serious questions about filings, press releases, or other communications from the company, take profits early and often. Ignoring red flags could cost you dearly if a suspension is invoked. There are no good outcomes for suspended stocks.
http://promotionstocksecrets.com/the-sec-just-suspended-my-stock-now-what/
that is from finra and it is in regards to broker dealers, not suspended companies.
I'm betting on this as the likely outcome...
Not all investigations result in formal disciplinary action. For example, if the violation is of a minor nature and there is an absence of customer harm or detrimental market impact, the matter may be resolved with an informal disciplinary action, such as the issuance of a Cautionary Action. While Cautionary Actions are considered by the staff in any future disciplinary matter, these actions do not constitute formal discipline and are not reportable on FINRA's Central Registration Depository (CRD) system or Form BD.
In addition, Enforcement may determine not to recommend formal disciplinary action following an investigation and may close the matter without further action.
They suspended the stock for a short period to verify the validity of their recent press releases.
nonsense. a suspension is not a time out. the sec has asked nothing of the company.
Do your own research and Watch for this stock to start trading again in the next 10 days or so
suspensions do not end early
trading will be open on the grey market 04/27/20.
Good to see someone is alive here. And I hope you’re right. I bought in Friday and it closed shop on Monday. 150k shares ready to make money.
I'm definitely still confident in PRLX and the stock.
They suspended the stock for a short period to verify the validity of their recent press releases. I'm fully confident the press releases are all valid and the company is in the right place right time with respect to being able to assist in helping to stop the coronavirus. Given the recent press, I'm thinking they should have meaningful revenues to report in the next quarterly report.
If you compare the business lines and patent development to the recent press releases, the company's entry into the Covid-19 market are right in line with their core business development and stated plans for the future.
Do your own research and Watch for this stock to start trading again in the next 10 days or so. Closely follow the news related to the stock split and FDA approval of tests. I like this one as a strong coronavirus penny play investment while we deal with COVID 19 as a society. I think we should all do well on this one if we time it right. IMO I donn't think we will see these low levels on the stock price again once it starts trading.
PRLX SEC Suspension "because of questions that have been raised about the accuracy and adequacy of information in the marketplace relating to Parallax common stock, including questions relating to statements Parallax made on its website and in press releases on March 12, March 16, March 17, March 23 and March 24, 2020 about its purported development of a rapid screening test for COVID-19 and its purported access to large quantities of COVID-19 diagnostic testing kits and personal protective equipment."
https://www.sec.gov/litigation/suspensions/2020/34-88618.pdf
Order:
https://www.sec.gov/litigation/suspensions/2020/34-88618-o.pdf
Parallax Health Sciences Announces Increased Customer Acquisition in Both Management and Diagnostics Divisions
https://ih.advfn.com/stock-market/USOTC/parallax-health-sciences-qb-PRLX/stock-news/82206521/parallax-health-sciences-announces-increased-custo
Lots of good news here. It's looking like they will continue to announce developments and updates that should give them strong momentum post split.
Another Possible Coronavirus Stock that Actually has 5 active Labs in the U.S. and 1 internationally and it’s at bottom bedrock price! https://www.linkedin.com/posts/willwaldrop_covid19testing-heathcare-thermocyler-activity-6649455695139872769-ukmC
Carter007 Out
DUMB Management... those good news was wasted, they will RS , then why release those good news now, tsk tsk. They should released it after the split.
I'm confident here because PRLX is Backed by strong Intellectual Property - How many of those companies you mention own intellectual property covering their testing unit and process? How many scam companies own and continue to create IP around multiple product offerings? Their home blood testing unit can run countless tests and they created this new one as soon as the coronavirus hit and they could access that specific virus strain. Watch for other positive news, this company is on the right path IMO, do your own research and keep the hate to a minimum.
PRLX is just another broke scam OTC ticker jumping on the COVID-19 bandwagon. Other recent OTC tickers announcing COVID-19 testing include PRED, DECN and NBDR. All also broke.
Between Sept. 2019 and the end of December 2019 there were 4.6 million reported cases of influenza in the U.S. 36,000 people were hospitalized and there were 2,100 related deaths due to flu. Where were these companies then?
The key investment point here is this is an at-home testing kit that anyone can use to secure a visit to a doctor. This can provide a huge advantage during this type of crisis where only wealthy patients or the most critical patients are currently being tested. This quick rollout of a new corona test for sale and the Data-Driven Outcomes Platform is a great sign this company is ready to address home health in a real way.
PRLX...06...NEW YORK, New York, March 24, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Parallax Health Sciences, Inc. (OTCQB: PRLX) (''Parallax'' or the ''Company''), an outcome-driven connected healthcare company, today announced that it has selected the antigens and antibodies that it will use as the markers for its rapid Coronavirus (“COVID-19”) screen test used on its FDA Cleared & Patented Target Diagnostics Test Platform.
https://www.otcmarkets.com/stock/PRLX/overview
Definitely setting up for a nice run here.
Parallax Announces Immediate Availability Point-of-Care COVID-19 Diagnostic Testing Kits, Personal Protection Equipment (PPE) and Medical Supplies
March 23, 2020 07:00 ET | Source: Parallax Health Sciences, Inc.
Company Benefits from Unique Chinese, Hong Kong, Macau Diagnostic Patent Rights, and Closes Deal to Help America Now
NEW YORK, NY, March 23, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Parallax Health Sciences, Inc. (OTCQB: PRLX) (''Parallax'' or the ''Company''), an outcome-driven connected healthcare company, today announced that a wholly-owned subsidiary, Parallax Diagnostics, Inc., has signed a contract with a medical distribution company in China owned by a prominent businessman well-known to the Company. Beginning today, the Company is accepting orders for and has immediate availability of the Coronavirus, (“COVID-19”) Point-of-Care Diagnostics Kits for American medical practices, hospitals, nursing operations, emergency centers, and nursing homes. In response to the present national market demand related to the COVID-19 pandemic the Company will also be providing immediate availability and access to Personal Protection Equipment, (“PPE”) including, but not limited to, FDA approved medical masks, protective sterile gowns, eye protecting goggles, face shields, ventilators, and other medical grade equipment. Parallax is also providing free downloads of its patented Good Health Outcomes Remote Patient Monitoring, (“RPM”) platform that enables comprehensive telehealth capabilities.
The Company has created a Government and Medical Practice website to process orders immediately. It has access to large inventories of all the available products and is offering the products in all fifty U.S. states and all U.S. territories from the Company’s website located at www.goodhealthoutcomes.com.
Nathaniel Bradley, President of Parallax Health Management, stated, “Our Good Health Outcomes remote patient monitoring application is the only system that has our patented Data-Driven Outcome and FotoDigm® technology.” Mr. Bradley continued, “these capabilities allow us to capture in real-time the test results achieved from the test kits we are offering through this partnership today. Further, our platform enables care providers to communicate with patients remotely and conserve their use of PPE and serve the communities of the U.S. remotely, leveraging encrypted and Health Insurance Portability and Accountability Act, (“HIPAA”) compliant video, audio and data communications.”
"While our relationship with these suppliers in China formulate into a much more meaningful and robust partnership near-term, our long-term goals remain intact related to our patented diagnostics portfolio and our ultimate distribution of industry leading handheld point-of-care diagnostics,” stated Paul Arena, Chief Executive Officer of Parallax Health Sciences, Inc. Mr. Arena added, “The deployment of lateral flow-through point-of-care testing kits combined with our Good Health Outcomes Remote Patient Monitoring technology was a natural and expedient way for us to begin. We were also fortunate to have the U.S. Federal Government lift sanctions and tariffs on medical products from China that opened up this opportunity, while we work out the bigger relationship, and for Parallax to immediately provide a solution to fill the void of overwhelming demand related to Personal Protective Equipment currently being experienced throughout the entire American medical system. We are committed to keeping the price fixed and as low as possible for U.S. Medical Companies that purchase from us and we are managing through a number of significant initial orders from New York, California, Arizona, and other states. We are focused on helping our medical system recover fully and for us all to get back to the important work that we all do.”
Corona Virus Investment Opportunity. Reviewing the latest on PRLX in relation to everything that is happening in the news with the Corona Virus and the shortage and need for new Corona testing kits. This company has the potential to be a strong opportunity to invest in a company that's in the right spot at the right time. The companies continuing to develop their products across several industry verticals and is backed by a diversified patent portfolio, combined with continued positive company news and broad U.S. and International patent portfolio coverage. IMO this flood of news and continued product and patent development from PRLX is a great indication this company is the real deal that's innovating in the right space and definitely not a scam. IMO This stock is a steal at these prices, but please always do your own research and good luck to all.
https://parallaxhealthsciences.com/investor-information
https://goodhealthoutcomes.com/patents
Parallax Receives Approval on its Registration Into U.S. Government's System for Award Management, (SAM)
https://finance.yahoo.com/news/parallax-receives-approval-registration-u-110010035.html
Corona Virus Investment Opportunity. Reviewing the latest on PRLX in relation to everything that is happening in the news with the Corona Virus and the shortage and need for new Corona testing kits. This company has the potential to be a strong opportunity to invest in a company that's in the right spot at the right time. The companies continuing to develop their products across several industry verticals and is backed by a diversified patent portfolio, combined with continued positive company news and broad U.S. and International patent portfolio coverage. IMO this flood of news and continued product and patent development from PRLX is a great indication this company is the real deal that's innovating in the right space and definitely not a scam. IMO This stock is a steal at these prices, but please always do your own research and good luck to all.
https://parallaxhealthsciences.com/investor-information
https://goodhealthoutcomes.com/patents
Parallax Receives Approval on its Registration Into U.S. Government's System for Award Management, (SAM)
https://finance.yahoo.com/news/parallax-receives-approval-registration-u-110010035.html
Reviewing the latest on PRLX in relation to everything that is happening in the news with the Corona Virus and the shortage and need for new Corona testing kits. This company has the potential to be a strong opportunity to invest in a company that's in the right spot at the right time. The companies continuing to develop their products across several industry verticals and is backed by a diversified patent portfolio, combined with continued positive company news and broad U.S. and International patent portfolio coverage. IMO this flood of news and continued product and patent development from PRLX is a great indication this company is the real deal that's innovating in the right space and definitely not a scam. IMO This stock is a steal at these prices, but please always do your own research and good luck to all.
https://parallaxhealthsciences.com/investor-information
https://goodhealthoutcomes.com/patents
Parallax Receives Approval on its Registration Into U.S. Government's System for Award Management, (SAM)
https://finance.yahoo.com/news/parallax-receives-approval-registration-u-110010035.html
Another corona virus scam exposed.. Get ready for all that converted to common at .05 to dump into bid
800,000 converted to common free tradeable at .05
https://www.otcmarkets.com/filing/html?id=13983216&guid=pNnCUFooDQjJQth
https://www.globenewswire.com/news-release/2020/03/12/1999352/0/en/Parallax-Health-Management-Announces-Immediate-Availability-of-its-Good-Health-Outcomes-Remote-Patient-Monitoring-Mobile-Application-for-Doctors-and-Their-Patients-Within-the-Unite.html
Pro at exposing the corona scams
Parallax Health Management Announces Immediate Availability of its Good Health Outcomes Remote Patient Monitoring Mobile Application for Doctors and Their Patients Within the United States
March 12, 2020 07:00 ET | Source: Parallax Health Sciences, Inc.
$8.3 Billion in Federal Emergency Funding from U.S. Congress Combined with Private Insurance Reimbursement Commitments Gives Boost to Telehealth Programs Addressing the COVID-19 Pandemic
NEW YORK, NY, March 12, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Parallax Health Sciences, Inc. (OTCQB: PRLX) (''Parallax'' or the ''Company''), an outcome-driven connected healthcare company, today announced its wholly owned subsidiary Parallax Health Management, Inc. focused on Remote Patient Monitoring (“RPM”) has the Health Insurance Portability and Accountability Act (“HIPAA”) compliant, proprietary and patented Good Health Outcomes™ platform now available for doctors and their patients within the United States. The scalable remote patient monitoring platform, available now from the Apple IOS and Google Play mobile application stores, is supported by Amazon’s AWS Secure Healthcare hosting centers and enables real-time secure audio and video conferencing, data capture, transmission and biometric monitoring data including temperature and respiratory monitoring devices. The scalable platform has been provisioned to accommodate the COVID-19 (coronavirus disease 2019) and can be used securely by authorized care providers to provide approved telehealth services.
Nathaniel Bradley, President of Parallax Health Management, stated, “At a news conference on Monday, March 9th, Seema Verma, the Administrator of the Centers for Medicare and Medicaid Services (“CMMS”) praised the Government’s efforts to expand the use of Telemedicine under Medicare, which is the Federal Program for people 65 years and older.” Mr. Bradley, who also serves as Chief Technology Officer of Parallax Health Sciences, went on to say, “The addition of private payers and their commitment to reimburse for approved telehealth services will allow patients to be monitored and to receive secure and robust telemedicine services supported through our Good Health Outcomes™ platform.”
Good Health Outcomes™ enables a unique offering that includes proprietary Fotodigm® data capture technology that enables the secure capture of data from any FDA approved monitoring device. It also features encrypted data management systems and seamless systems integration with any secure electronic medical record (“EMR”) and medical billing platforms. Our Good Health Outcomes™ is the only mobile application system to feature patented data-driven outcomes technology known as reliable evidenced based outcomes optimization technology, (“R.E.B.O.O.T.”) that allows for automated interventions and mobile alerts.
From what is understood by infectious disease experts, the COVID-19 (coronavirus disease 2019) is different due to the unknown factors surrounding transmission and its effects on patients,” stated Paul Arena, Chief Executive Officer for Parallax Health Science. Mr. Arena continued, “the coronavirus is still being figured out and there have been a significant number of deaths, given the high level of uncertainty surrounding this pandemic it is scary to both patients and the general public. Our healthcare solutions and ability to remotely diagnose and monitor patients provides healthcare providers with tools to become less challenged and to make accurate recommendations even when there are still many unknowns facing the mass population. Yesterday we announced our strategic initiative for the creation of a rapid screening test on our VT-1000 diagnostics device for the Covid-19 that when available soon will produce results within 15 minutes. Our integrated remote patient monitoring and diagnostic platform can be useful to assess and comfort patients in alternative settings such as their home, and also for determining which patients need to be seen in the hospital or if urgent care is appropriate. Our Good Health Outcomes™ platform can enable healthcare providers to treat isolated patients and help to prevent the spread of what is becoming an extremely contagious virus.”
Any Doctor, Critical Access Hospital, Hospital or nursing operation can download and register for free immediately at the Parallax website:
https://goodhealthoutcomes.com/good-health-outcomes
Crazy run coming here... Zzzzzzzzz
Huge volume last 2 days
Parallax Health up on planned coronavirus test
Mar. 11, 2020 11:03 AM ET|About: Parallax Health Scienc... (PRLX)|By: Douglas W. House, SA News Editor
Thinly traded nano cap Parallax Health Sciences (OTCPK:PRLX +13%) is, yet another, would-be player in the mad dash for a rapid screening test for COVID-19.
Today, it announced that subsidiary Parallax Diagnostics intends to in-license and develop monoclonal and polyclonal antibodies for such a test based on its VT-1000 immunoassay platform. Available resources appear to be an issue since it is seeking partners to accelerate the development.
Hardly any selling today= waiting for MUCH higher ground. If an shrimp Company can go from .01 to .95...then what will this do with an CV test kit that will be needed as the CV continues to grow in rapid numbers worldwide?! Holding strong here. Was thinking .20's+, but this could go huge when looking at AYTU going from .37 to 2.95 in regards to their testing kit news. Talk about lotto..LOL.. JMO & GL
Followers
|
37
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1416
|
Created
|
04/12/09
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |